« Return to News | Drug Sponsors

Chiesi Group to acquire Zymenex

Tuesday, August 27, 2013 10:30 AM

Chiesi Group, a European pharmaceutical company, has agreed to acquire Danish biopharmaceutical company Zymenex and its related group of companies, a biopharmaceutical group focused on R&D of biologic therapeutics for the treatment of rare and life threatening genetic diseases. Terms of the transaction were not disclosed.

The acquisition of Zymenex includes Lamazym (rhLAMAN), a phase III recombinant enzyme indicated for use to treat patients suffering from alpha-Mannosidosis, as well as other early-stage compounds. Chiesi will leverage its experience in commercializing pharmaceutical solutions to bring the treatment to patients with alpha-mannosidosis worldwide.

"Given the rarity of the condition and the importance of being close to the patients, we will consider setting up a standalone rare disease unit that would cover all major geographies, including the U.S.,” said Ugo Di Francesco, chief executive officer of Chiesi.

Chiesi expects to gradually integrate Zymenex into its R&D structure and retain the Zymenex and Lamazym brands.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.